Penn Transplant Institute

Clinical Trials

Heart Transplant
A facilitated access program to provide everolimus (RAD) for maintenance patients completing therapy in RAD trials in solid organ transplantation
A six-month, multicenter, randomized, open full label study of the safety, tolerability and efficacy of two neoral doses in addition to cerican and steroids in de novo heart transplant recipients
A pilot study of cardiothoracic (CT) coronary angiography for the detection of transplant arteriopathy
Human heart tissue protocol
Kidney Transplant
One-year exploratory study to evaluate the efficacy and safety of belimumab for normalization of alloantibody levels in sensitized patients awaiting kidney transplantation.
Changes in skeletal microarchitecture following renal transplantation
Genetic determinants of kidney transplant outcomes
Vascular calcification in kidney transplant recipients
Clinical trials in organ transplantation (CTOT)
A phase IV, randomized, open-label, comparative, single-center study to assess gastrointestinal adverse event outcomes of de novo African American kidney transplant recipients treated with Prograf® (tacrolimus) /CellCept® (mycophenolate mofetil)/corticosteroids versus Prograf (tacrolimus)/Myfortic® (enteric-coated mycophenolate sodium)/corticosteroids
Liver Transplant
Genes related to HCC progression in liver transplant recipients
Molecular profiling and donor and recipient pro inflammatory and alloimmune response
Tissue and serum bank
Gene expression and regenerative pathways in donor livers
  • Investigator: Kim Olthoff, MD
A phase II trial to assess the safety of immunosuppression withdrawal in liver transplant recipients with hepatitis C
Validation of serum markers for the early detection of hepatocellular carcinoma (DCP)
A2 ALL: adult-to-adult living donor liver transplant cohort study)
A2 ALL: adult-to-adult living donor liver transplant cohort study)
Clinical, immunologic and pharmacologic consequences of liver transplantation in people with HIV infection
  • Investigator: Kim Olthoff, MD
Comparative evaluation of inhibitor treatments in liver allograft recipients
Comparative safety and efficacy study of prophylactic interferon following liver transplantation for hepatitis C
Safety and efficacy study of N-acetylcysteine in the treatment of acute liver failure not caused by acetaminophen in adult patients
An observational database of patients who receive orthotopic liver transplantation (OLT) for hepatitis B
Comparison of HepeX-BTM, a mixture of two monoclonal antibodies, to hepatitis B immune globulin in patients who have received hepatic allografts for treatment of end-stage liver disease due to hepatitis B virus infection
Intravenous terlipressin in patients with hepatorenal syndrome type I
Lung Transplant
Dietary Antioxidant Therapy in Patients Awaiting Lung Transplantation
Clinical Risk Factors of Primary Graft Failure, a Multicenter Study
Genetics of Primary Graft Failure, a Multicenter Study
Clinical Trials in Organ Transplantation
The HLA Antibodies after Lung Transplantation (HALT) Study

Advanced Lung Disease Research Studies

Bronchiectasis

A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX1), Gilead
A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis Patients from Major Clinical and Research Institutions (NON-TREATMENT)

IPF

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, InterMune (TREATMENT)
NAC vs. Placebo, PANTHER – IPFNet trial (TREATMENT)
A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline, in patients with Idiopathic Pulmonary Fibrosis (TREATMENT)
PA-IPF Registry(NON-TREATMENT)
Pancreas and Islet Cell Transplant
Islet transplantation in type 1 diabetes using immunosuppression and strategies to improve long term graft survival
Using anti-B lymphocyte agent rituximab (Rituxan) to improve long-term graft survival
Islet transplantation vs. intensive insulin therapy in patients with type 1 diabetes who have already received a kidney transplant